474
S. Gorsuch et al. / Bioorg. Med. Chem. 17 (2009) 467–474
compound as an off white solid powder (60 mg, 0.26 mmol, 70%).
Mp 99–102 °C; (found: C, 51.39; H, 3.44; N, 23.91; C10H8N4OS re-
quires C, 51.71; H, 3.47, N, 24.12); dH (250 MHz, CDCl3, TMS)
4.29 (2H, s, CH2), 7.33–7.61 (5H, m, Ph), 8.12 (1H, s, 5-H); dC
(62 MHz, CDCl3); 48.1, 122.7, 124.8, 127.9, 129.8, 136.0, 136.9,
166.0; FAB-HRMS: measured 233.0505; calcd for C10H9N4OS
(M+H)+: 233.0497.
References and notes
1. Bhalla, K. N. J. Clin. Oncol. 2005, 23 17, 3971.
2. Jenuwein, T.; Allis, C. D. Science 2001, 293, 1074.
3. Kristeleit, R.; Stimson, L.; Workman, P.; Aherne, G. W. Expert Opin. Emerg. Drugs
2004, 91, 135.
4. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Nat.
Rev. Cancer 2001, 1, 194.
5. Strahl, B. D.; Allis, C. D. Nature 2000, 403, 41.
6. Bernstein, B. E.; Schreiber, S. L. Chem. Biol. 2002, 911, 1167.
7. Kouzarides, T. Curr. Opin. Gen. Dev. 1999, 9, 40.
8. Adcock, I. M.; Ito, K.; Barnes, P. J. COPD 2005, 2, 445.
9. Barnes, P. J. Immunol. Allergy Clin. 2005, 25, 451.
4.18. 4-Methyl-5-methoxy-2-phenyl-isothiazol-3(2H)-one (35)
A solution of 4-methyl-5-chloro-isothiazol-3(2H)-one (50 mg,
0.22 mmol) and NaOMe (24 mg, 0.44 mmol) in MeOH (7.5 mL)
were heated at reflux for 5 h. After this period the resultant mix-
ture was evaporated to afford a yellow oil. Purification by flash col-
umn chromatography (30% EtOAc/hexane) afforded the title
compound as a colourless oil (12 mg, 0.054 mmol, 24%). dH
(250 MHz, CDCl3, TMS) 1.92 (3H, s, CH3), 3.97 (3H, s, CH3O),
7.22–7.58 (5H, m, Ph); dC (62 MHz, CDCl3) 9.1, 59.7, 101.5, 120.3,
124.9, 126.9, 129.6, 137.5, 168.0; FAB-HRMS: measured
222.0575; calcd for C11H12NO2S (M+H)+: 222.0589.
10. Barnes, P. J.; Adcock, I. M.; Ito, K. Eur. Respir. J. 2005, 25, 552.
11. Santos-Rosa, H.; Caldas, C. Eur. J. Cancer 2005, 41 16, 2381.
12. Balasubramanyam, K.; Altaf, V.; Varier, R. A.; Swaminathan, M.; Ravindran, A.;
Sadhale, P. P.; Kundu, T. K. J. Biol. Chem. 2004, 7732, 33716.
13. Wolffe, A. P. Oncogene 2001, 20, 2980.
14. Mahlknecht, U.; Hoelzer, D. Mol. Med. 2000, 6, 623.
15. Timmermann, S.; Lehrmann, H.; Polesskaya, A.; Harel-Bellan, A. Cell Mol. Life
Sci. 2001, 58, 728.
16. Reiter, R.; Wellstein, A.; Riegel, A. T. J. Biol. Chem. 2001, 276, 39736.
17. Debes, J. D.; Sebo, T. J.; Lohse, C. M.; Murphy, L. M.; Haugen, D. A. L.; Tindall, D. J.
Cancer Res. 2003, 63, 7638.
18. Lau, O. D.; Kundu, T. K.; Soccio, R. E. Mol. Cell. 2000, 5, 589.
19. Cebrat, M.; Kim, C. M.; Thompson, P. R.; Daugherty, M.; Cole, P. A. Bioorg. Med.
Chem. 2003, 11, 3307.
20. Sagar, V.; Zheng, W.; Thompson, P. R.; Cole, P. A. Bioorg. Med. Chem. 2004, 12,
3383.
4.19. 2-(Phenyl)-isothiazolo[5,4-b]pyridin-3(2H)-one (38)
21. Zheng, Y.; Balasubramanyam, K.; Cebrat, M.; Buck, D.; Guidez, F.; Zelent, A.;
Alani, R. M.; Cole, P. A. J. Am. Chem. Soc. 2005, 127, 17182.
22. Balasubramanyam, K.; Swaminathan, V.; Ranganathan, A.; Kundu, T. K. J. Biol.
Chem. 2003, 278, 19134.
23. Eliseeva, E. D.; Valkov, V.; Jung, M.; Jung, M. O. Mol. Cancer Ther. 2007, 6, 2391.
24. Mantelingu, K.; Reddy, B. A. A.; Swaminathan, V.; Kishore, A. H.; Siddappa, N.
B.; Kumar, G. V. P.; Nagashankar, G.; Natesh, N.; Roy, S.; Sadhale, P. P.; Ranga,
U.; Narayana, C.; Kundu, T. K. Chem. Biol. 2007, 14, 645.
25. Biel, M.; Kretsovali, A.; Karatzali, E.; Papamatheakis, J.; Giannis, A. Angew.
Chem., Int. Ed. 2004, 43, 3974.
26. Mai, A.; Cheng, D.; Bedford, M. T.; Valente, S.; Nebbioso, A.; Perrone, A.;
Brosch, G.; Sbardella, G.; De Bellis, F.; Miceli, M.; Altucci, L. J. Med. Chem.
2008, 51, 2279.
27. Sbardella, G.; Castellano, S.; Vicidomini, C.; Rotili, D.; Nebbioso, A.; Miceli, M.;
Altucci, L.; Mai, A. Bioorg. Med. Chem. Lett. 2008, 18, 2788.
28. Stimson, L.; Rowlands, M. G.; Newbatt, Y. M.; Smith, N. F.; Raynaud, F. I.;
Rogers, P.; Bavetsias, V.; Gorsuch, S.; Jarman, M.; Bannister, A.; Kouzarides, T.;
McDonald, E.; Workman, P.; Aherne, G. W. Mol. Cancer Ther. 2005, 4, 1521.
29. Beeley, N. R. A.; Harwood, L. M.; Hedger, P. C. J. Chem. Soc., Perkin Trans 1 1994,
2245.
PyBOPÒ (1.68 g, 3.22 mmol) was added portionwise to a stirred
solution of 3-mercaptonicotinic acid (500 mg, 3.22 mmol), diisopro-
pylethylamine (168 mL, 9.7 mmol) and aniline (285 mg, 3.06 mmol)
in dichloromethane (20 mL) at 0 °C. The mixture was stirred for
30 min and then warmed to room temperature for 1 h. The reaction
mixture was diluted satd NaHCO3 (10 mL) and extracted with
dichloromethane (2 ꢁ 10 mL). The combined organic extracts were
then further extracted with 1 M NaOH (2 ꢁ 20 mL). The combined
alkaline extracts were cooled to 0 °C and carefully acidified to pH 1
using 2 M HCl. The precipitate thus obtained was filtered, rinsed
with H2O (10 mL) and then recrystallised from methanol to afford
N-(phenyl)-1,2-dihydro-2-thioxo-3-pyridecarboxamide 37 as
a
highly crystalline yellow solid (0.52 g, 2.26 mmol, 70%).
Triethylamine (0.12 mL, 0.87 mmol) was added dropwise to a
stirred slurry of N-(phenyl)-1,2-dihydro-2-thioxo-3-pyridecarbox-
amide (100 mg, 0.43 mmol) and iodine (115 mg, 0.456 mmol) in
dichloromethane (10 mL) at room temperature. After 60 min the
reaction mixture was washed with satd Na2S2O3 and extracted into
dichloromethane (3 ꢁ 5 mL). The combined extracts were dried
over Na2SO4 and evaporated in vacuo. Flash column chromatogra-
phy of the residue (50% EtOAc/Hexane) afforded 2-(phenyl)-iso-
thiazolo[5,4-b]pyridin-3-one (38) as a silvery crystalline solid
(84 mg, 0.37 mmol, 85%). 1H NMR data for this compound was in
agreement with the literature.35
30. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.;
Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana,
J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.;
Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.;
Adams, J. L. Bioorg. Med. Chem. 1997, 5, 49.
31. Ravikumar, K. S.; Begue, J. P.; Bonnet-Delpon, D. Tetrahedron Lett. 1998, 39,
3141.
32. Bergmeier, S. C.; Arason, K. M. Tetrahedron Lett. 2000, 41, 5799.
33. Wright, S. W.; Petraitis, J. J.; Freimark, B.; Giannaras, J. V.; Pratta, M. A.; Sherk, S.
R.; Williams, J. M.; Magolda, R. L.; Arner, E. C. Bioorg. Med. Chem. 1996, 4, 851.
34. Lewis, S. N.; Miller, G. A.; Hausman, M.; Szamborski, E. C. J. Heterocycl. Chem.
1971, 8, 571.
35. Monge, A.; Martinez-Merino, V.; Fernandez-Alvarez, E. J. Heterocycl. Chem.
1985, 22, 1353.
36. Turlais, F.; Hardcastle, A.; Rowlands, M.; Newbatt, Y.; Bannister, A. S.;
Kouzarides, T.; Workman, P.; Aherne, G. W. Anal. Biochem. 2001, 298, 62.
37. Collier, P. J.; Ramsey, A.; Waigh, R. D.; Douglas, K. T.; Austin, P.; Gilbert, P. J.
Appl. Bact. 1990, 69, 578.
38. Hayakawa, N.; Nozawa, K.; Ogawa, A.; Kato, N.; Yoshida, K.; Akamatsu, K.;
Tsuchiya, M.; Nagasaka, A.; Yoshida, S. Biochemistry 1999, 38, 11501.
39. Trevillyan, J. M.; Chiou, X. C.; Ballaron, S. J.; Tang, Q. M.; Buko, A.; Sheets, M. P.;
Smith, M. L.; Putman, B.; Wiedeman, P.; Madar, T. N.; Smith, D. H. T.; Gubbins,
E. J.; Warrior, U. P.; Chen, Y.-M.; Mollison, K. W.; Faltynek, C. R.; Djuric, S. W.
Arch. Biochem. Biophys. 1999, 364, 19.
40. Khalaj, A.; Adibpour, N.; Shahverdi, A. R.; Daneshtalab, M. Eur. J. Med. Chem.
2004, 699.
41. Achmatowicz, B.; Raubo, P.; Wicha, J. J. Org. Chem. 1992, 57, 6593.
Acknowledgments
The work of the Cancer Research UK Centre for Cancer Thera-
peutics is funded primarily by Cancer Research UK [CUK] Pro-
gramme Grant C309/A2187. Paul Workman is a Cancer Research
UK Life Fellow. We thank Dr. Andrew Bannister and Prof Tony
Kouzarides (Wellcome Trust/Cancer Research UK Gurdon Institute,
University of Cambridge, UK) for providing the recombinant PCAF
enzyme. We also thank Dr. Amin Mirza and Angela Hayes for
obtaining the ESI spectra. The authors are grateful to Chroma Ther-
apeutics for valuable discussions.